Omega-3 fatty acids inhibit tumor growth in a rat model of bladder cancer

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Parada, Belmiro ^a,b   Reis, Flávio ^a   Cerejo, Raquel ^a   Garrido, Patrícia ^a   Sereno, José ^a   Xavier Cunha, Maria ^b   Neto, Paula ^b   Mota, Alfredo ^b   Figueiredo, Arnaldo ^b   Teixeira, Frederico ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD31 ANTIGEN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; OMEGA 3 FATTY ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; IN VIVO STUDY; MALE; NONHUMAN; RAT; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; UROTHELIUM; ANIMAL; BLADDER; BLADDER TUMOR; BLOOD; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DISEASE MODEL; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; WISTAR RAT; DRUG EFFECTS; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTIGENS, CD31; CELL PROLIFERATION; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; OXIDATION-REDUCTION; RATS; RATS, WISTAR; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84880164934     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/368178     Document Type: Article

References (62)

1. Grasso M., Bladder cancer: a major public health issue. European Urology 2008 7 7 510 515 2-s2.0-43849088953 10.1016/j.eursup.2008.04.001
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P., Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology 2007 18 3 581 592 2-s2.0-33847638137 10.1093/annonc/mdl498
3. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., Kiemeney L., Kriegmair M., Montironi R., Murphy W. M., Sesterhenn I. A., Tachibana M., Weider J., Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005 66 6, supplement 4 34 2-s2.0-30044441045 10.1016/j.urology.2005.07.062
4. Sylvester R. J., Van Der Meijden A. P. M., Oosterlinck W., Witjes J. A., Bouffioux C., Denis L., Newling D. W. W., Kurth K., Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology 2006 49 3 466 475 2-s2.0-32944465832 10.1016/j.eururo.2005.12. 031
5. Malkowicz S. B., van Poppel H., Mickisch G., Pansadoro V., Thüroff J., Soloway M. S., Chang S., Benson M., Fukui I., Muscle-invasive urothelial carcinoma of the bladder. Urology 2007 69 1, supplement 3 16 2-s2.0-33846635592 10.1016/j.urology.2006.09.028
6. Zeegers M. P., Tan F. E., Dorant E., Van Den Brandt P. A., The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000 66 4 34
7. Kogevinas M., 'T Mannetje A., Cordier S., Ranft U., González C. A., Vineis P., Chang-Claude J., Lynge E., Wahrendorf J., Tzonou A., Jöckel K.-H., Serra C., Porru S., Hours M., Greiser E., Boffetta P., Occupation and bladder cancer among men in Western Europe. Cancer Causes and Control 2003 14 10 907 914 2-s2.0-9144225349 10.1023/B:CACO.0000007962.19066.9c
8. Wolff D. J., The genetics of bladder cancer: a cytogeneticist's perspective. Cytogenetic and Genome Research 2007 118 2-4 177 181 2-s2.0-36249004425 10.1159/000108298
9. Baffa R., Letko J., McClung C., LeNoir J., Vecchione A., Gomella L. G., Molecular genetics of bladder cancer: targets for diagnosis and therapy. Journal of Experimental and Clinical Cancer Research 2006 25 2 145 160 2-s2.0-33746370696
10. Kunze E., Schauer A., Schatt S., Stages of transformation in the development of N butyl N (4 hydroxybutyl) nitrosamine induced transitional cell carcinomas in the urinary bladder of rats. Zeitschrift fur Krebsforschung und Klinische Onkologie 1976 87 2 139 160 2-s2.0-0017089748
11. Fukushima S., Hirose M., Tsuda H., Histological classification of urinary bladder cancers in rats induced by N butyl N (4 hydroxybutyl)nitrosamine. Gann 1976 67 1 81 90 2-s2.0-0017228708
12. Oliveira P. A., Colaço A., De La Cruz P L. F., Lopes C., Experimental bladder carcinogenesis-rodent models. Experimental Oncology 2006 28 1 2 11 2-s2.0-33646019838
13. Montironi R., Mazzucchelli R., Preneoplastic lesions and conditions of the urinary bladder. EAU Update Series 2003 1 2 53 63 2-s2.0-15744398205 10.1016/S1570-9124(03)00023-0
14. Sauter G., Algaba F., Amin M., Eble J. N., Sauter G., Epstein J. L., Sesterhenn I., Tumors of the urinary system: non-invasive urothelial neoplasias. WHO Classification of Tumors of the Urinary System and Male Genital Organs 2004 Lyon, France IARCC Press 29 34
15. Leppert J. T., Shvarts O., Kawaoka K., Lieberman R., Belldegrun A. S., Pantuck A. J., Prevention of bladder cancer: a review. European Urology 2006 49 2 226 234 2-s2.0-32044443426 10.1016/j.eururo.2005.12.011
16. Parada B., Sereno J., Reis F., Teixeira-Lemos E., Garrido P., Pinto A. F., Cunha M. F., Pinto R., Mota A., Figueiredo A., Teixeira F., Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biology and Therapy 2009 8 17 1615 1622 2-s2.0-70350306703 10.4161/cbt.8.17.9199
17. Parada B., Reis F., Figueiredo A., Nunes P., Teixeira-Lemos E., Garrido P., Sereno J., Pinto R., Cunha M. F. X., Neto P., Santos P., Velada I., Mota A., Teixeira F., Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. British Journal of Urology International 2011 107 1 135 143 2-s2.0-78650640212 10.1111/j.1464-410X.2010.09326.x
18. Parada B., Reis F., Pinto A., Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. International Journal of Molecular Science 2012 13 7 8482 8499
19. Fernandes J. C., Sereno J., Garrido P., Inhibition of bladder tumor growth by chitooligosaccharides in an experimental carcinogenesis model. Marine Drugs 2012 10 12 2661 2675
20. La Guardia M., Giammanco S., Di Majo D., Tabacchi G., Tripoli E., Giammanco M., Omega 3 fatty acids: biological activity and effects on human health. Panminerva Medica 2005 47 4 245 257 2-s2.0-33645274903
21. Simopoulos A. P., Omega-6/omega-3 essential fatty acids: biological effects. World Review of Nutrition and Dietetics 2009 99 1 16 2-s2.0-62449104205 10.1159/000192755
22. De Lorgeril M., Essential polyunsaturated fatty acids, inflammation, atherosclerosis and cardiovascular diseases. Sub-Cellular Biochemistry 2007 42 283 297 2-s2.0-34547605356
23. Farooqui A. A., N-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation. Current Medicinal Chemistry 2012 19 4 532 543 2-s2.0-84857579456 10.2174/092986712798918851
24. Calder P. C., The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Molecular Nutrients & Food Research 2012 56 7 1073 1080
25. Raffaelli L., Serini S., Piccioni E., Manicone P. F., Berardi D., Perfetti G., Calviello G., N-3 polyunsaturated fatty acid effect in periodontal disease: state of art and possible mechanisms involved. International Journal of Immunopathology and Pharmacology 2008 21 2 261 266 2-s2.0-47249131617
26. Serini S., Piccioni E., Calviello G., Dietary n-3 PUFA vascular targeting and the prevention of tumor growth and age-related macular degeneration. Current Medicinal Chemistry 2009 16 34 4511 4526 2-s2.0-72449165993 10.2174/092986709789760788
27. MacLean C. H., Newberry S. J., Mojica W. A., Khanna P., Issa A. M., Suttorp M. J., Lim Y.-W., Traina S. B., Hilton L., Garland R., Morton S. C., Effects of omega-3 fatty acids on cancer risk: a systematic review. Journal of the American Medical Association 2006 295 4 403 415 2-s2.0-31344478294 10.1001/jama.295.4.403
28. Berquin I. M., Edwards I. J., Chen Y. Q., Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Letters 2008 269 2 363 377 2-s2.0-51349137876 10.1016/j.canlet.2008.03.044
29. Calviello G., Serini S., Piccioni E., Pessina G., Antineoplastic effects of N-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutrition and Cancer 2009 61 3 287 301 2-s2.0-67649396491 10.1080/01635580802582777
30. Maclean C. H., Newberry S. J., Mojica W. A., Issa A., Khanna P., Lim Y. W., Morton S. C., Suttorp M., Tu W., Hilton L. G., Garland R. H., Traina S. B., Shekelle P. G., Effects of omega-3 fatty acids on cancer. Evidence Report-Technology Assessment 2005 113 1 4 2-s2.0-15744398487
31. Brausi M., Witjes J. A., Lamm D., Persad R., Palou J., Colombel M., Buckley R., Soloway M., Akaza H., Böhle A., A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. Journal of Urology 2011 186 6 2158 2167 2-s2.0-80755172266 10.1016/j.juro.2011.07.076
32. Lattouf J.-B., Chemoprevention in bladder cancer: what's new? Journal of the Canadian Urological Association 2009 3 6, supplement S184 S187 2-s2.0-75849125843
33. Stocco B., Toledo K., Salvador M., Paulo M., Koyama N., Torqueti Toloi M. R., Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas 2012 72 1 72 78 2-s2.0-84859551307 10.1016/j.maturitas.2012.02.004
34. Goossens M. E., Buntinx F., Joniau S., Ackaert K., Ameye F., Billiet I., Braeckman J., Breugelmans A., Darras J., Dilen K., Goeman L., Kellen E., Tombal B., Van Bruwaene S., Van Cleyenbreugel B., Van der Aa F., Vekemans K., van Poppel H., Zeegers M. P., Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. BMC Urology 2012 12, article 8 2-s2.0-84858593968 10.1186/1471-2490-12-8
35. Hori S., Butler E., McLoughlin J., Prostate cancer and diet: food for thought? British Journal of Urology International 2012 107 9 1348 1359
36. Cockbain A. J., Toogood G. J., Hull M. A., Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut 2012 61 1 135 149 2-s2.0-83555176443 10.1136/gut.2010.233718
37. Signori C., El-Bayoumy K., Russo J., Thompson H. J., Richie J. P., Hartman T. J., Manni A., Chemoprevention of breast cancer by fish oil in preclinical models: trials and tribulations. Cancer Research 2011 71 19 6091 6096 2-s2.0-80053381640 10.1158/0008-5472.CAN-11-0977
38. Norat T., Bingham S., Ferrari P., Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. Journal of National Cancer Institute 2005 97 12 906 916
39. Manson J. E., Bassuk S. S., Lee I.-M., Cook N. R., Albert M. A., Gordon D., Zaharris E., MacFadyen J. G., Danielson E., Lin J., Zhang S. M., Buring J. E., The Vitamin D and Omega-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials 2012 33 1 159 171 2-s2.0-84855341899 10.1016/j.cct.2011.09.009
40. Molinari R., D'Eliseo D., Manzi L., Zolla L., Velotti F., Merendino N., The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure. Cancer Immunology, Immunotherapy 2011 60 10 1503 1507 2-s2.0-80054099486 10.1007/s00262-011-1074-7
41. Mackie S. J., Sharma D. M., Cooper A. J., Harris N. M., Lwaleed B. A., Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin. Prostaglandins Leukotrienes and Essential Fatty Acids 2006 75 6 367 373 2-s2.0-33750483260 10.1016/j.plefa.2006.07.002
42. Eynard A. R., Is the risk of the urinary tract tumorigenesis enhancced by a marginal chronic essential fatty acid deficiency (EFAD)? Nutrition 1998 14 2 211 216 2-s2.0-0032005109 10.1016/S0899-9007(97)00426-7
43. McClinton S., Moffat L. E. F., Horrobin D. F., Manku M. S., Abnormalities of essential fatty acid distribution in the plasma phospholipids of patients with bladder cancer. British Journal of Cancer 1991 63 2 314 316 2-s2.0-0026021017
44. Brinkman M. T., Karagas M. R., Zens M. S., Schned A. R., Reulen R. C., Zeegers M. P., Intake of α -linolenic acid and other fatty acids in relation to the risk of bladder cancer: results from the New Hampshire case-control study. British Journal of Nutrition 2011 106 7 1070 1077 2-s2.0-84856386165 10.1017/S0007114511001346
45. Ohtani M., Kakizoe T., Nishio Y., Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Research 1986 46 4 2001 2004 2-s2.0-0022647132
46. Hattori K., Iida K., Joraku A., Tsukamoto S., Akaza H., Oyasu R., Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. British Journal of Urology International 2006 97 3 640 643 2-s2.0-33645007678 10.1111/j.1464-410X.2006.06053.x
47. Federico A., Morgillo F., Tuccillo C., Ciardiello F., Loguercio C., Chronic inflammation and oxidative stress in human carcinogenesis. International Journal of Cancer 2007 121 11 2381 2386 2-s2.0-35648946229 10.1002/ijc.23192
48. Calviello G., Palozza P., Piccioni E., Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. International Journal of Cancer 1998 75 5 699 705
49. Barascu A., Besson P., Le Floch O., Bougnoux P., Jourdan M.-L., CDK1-cyclin B1 mediates the inhibition of proliferation induced by omega-3 fatty acids in MDA-MB-231 breast cancer cells. International Journal of Biochemistry and Cell Biology 2006 38 2 196 208 2-s2.0-27744447729 10.1016/j.biocel.2005.08. 015
50. Boudreau M. D., Sohn K. H., Rhee S. H., Lee S. W., Hunt J. D., Hwang D. H., Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways. Cancer Research 2001 61 4 1386 1391 2-s2.0-0035866384
51. Kobayashi N., Barnard R. J., Henning S. M., Elashoff D., Reddy S. T., Cohen P., Leung P., Hong-Gonzalez J., Freedland S. J., Said J., Gui D., Seeram N. P., Popoviciu L. M., Bagga D., Heber D., Glaspy J. A., Aronson W. J., Effect of altering dietary ω -6/ ω -3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clinical Cancer Research 2006 12 15 4662 4670 2-s2.0-33748090269 10.1158/1078-0432.CCR-06-0459
52. Hardman W. E., (n-3) fatty acids and cancer therapy. Journal of Nutrition 2004 134 12, supplement 3427S 3430S 2-s2.0-9744228743
53. Hendrickse C. W., Keighley M. R. B., Neoptolemos J. P., Dietary ω -3 fats reduce proliferation and tumor yields at colorectal anastomosis in rats. Gastroenterology 1995 109 2 431 439 2-s2.0-0028977960 10.1016/0016-5085(95) 90330-5
54. Fini L., Piazzi G., Ceccarelli C., Daoud Y., Belluzzi A., Munarini A., Graziani G., Fogliano V., Selgrad M., Garcia M., Gasbarrini A., Genta R. M., Boland C. R., Ricciardiello L., Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in ApcMin/+ mice. Clinical Cancer Research 2010 16 23 5703 5711 2-s2.0-78650364506 10.1158/1078-0432.CCR-10-1990
55. Calviello G., Serini S., Piccioni E., n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved. Current Medicinal Chemistry 2007 14 29 3059 3069 2-s2.0-36849066352 10.2174/ 092986707782793934
56. Boutros C., Somasundar P., Razzak A., Helton S., Espat N. J., Omega-3 fatty acids: investigations from cytokine regulation to pancreatic cancer gene suppression. Archives of Surgery 2010 145 6 515 520 2-s2.0-77953863359 10.1001/archsurg.2010.91
57. Spencer L., Mann C., Metcalfe M., Webb M., Pollard C., Spencer D., Berry D., Steward W., Dennison A., The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. European Journal of Cancer 2009 45 12 2077 2086 2-s2.0-67650938102 10.1016/j.ejca.2009.04.026
58. Calviello G., Palozza P., Di Nicuolo F., Maggiano N., Bartoli G. M., n-3 PUFA dietary supplementation inhibits proliferation and store- operated calcium influx in thymoma cells growing in Balb/c mice. Journal of Lipid Research 2000 41 2 182 188 2-s2.0-0034001468
59. El Gehani K., Al-Kikhia L., Mansuri N., Syrjänen K., Al-Fituri O., Elzagheid A., Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for Factor VIII and CD31. Libyan Journal of Medicine 2011 6, article 6016 2-s2.0-80053602302 10.3402/ljm.v6i0.6016
60. Harris R. E., Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Sub-cellular biochemistry 2007 42 93 126 2-s2.0-34547578958
61. Vecchini A., Ceccarelli V., Susta F., Caligiana P., Orvietani P., Binaglia L., Nocentini G., Riccardi C., Calviello G., Palozza P., Maggiano N., Di Nardo P., Dietary α -linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells. Journal of Lipid Research 2004 45 2 308 316 2-s2.0-10744224371 10.1194/jlr.M300396-JLR200
62. Vecchio A. J., Simmons D. M., Malkowski M. G., Structural basis of fatty acid substrate binding to cyclooxygenase-2. Journal of Biological Chemistry 2010 285 29 22152 22163 2-s2.0-77954611060 10.1074/jbc.M110.119867